Gloo Holdings Inc (GLOO) Q4 2025 Earnings Call Transcript

Why It Matters

The results validate Glaukos' dual‑track strategy of expanding interventional glaucoma treatments while entering the rare‑disease corneal market, positioning the company for sustained double‑digit growth and broader payer coverage.

Key Takeaways

• Q4 sales $143.1M, up 36% YoY.
• Full-year 2025 sales $507.4M, record.
• 2026 sales guidance $600‑$620M, >20% growth.
• iDose TR drives 53% U.S. glaucoma sales growth.
• Epioxa approved, first topical keratoconus therapy.

Pulse Analysis

Glaukos' Q4 performance underscores the potency of its interventional glaucoma platform. The iDose TR micro‑dose system, now a cornerstone of U.S. glaucoma therapy, delivered a 53% surge in franchise revenue, reflecting strong physician adoption and expanding surgeon training programs. This momentum, combined with robust international growth, propelled the company past the $500 million annual sales threshold, a milestone that enhances its credibility with investors and sets a higher baseline for future earnings forecasts. The firm’s ability to scale both product sales and operational capacity signals a maturing business model in the ophthalmic sector.

The FDA clearance of Epioxa marks Glaukos' entry into the rare‑disease arena, offering the first non‑epithelial, topical treatment for keratoconus. Early payer engagement covering roughly half of commercially insured lives and the rapid deployment of O2n delivery systems to sites serving 50% of the U.S. population illustrate a proactive market‑access strategy. While initial uptake may be moderated by the temporary technology J code, the anticipated permanent J code in July 2026 should accelerate reimbursement and broaden adoption, positioning Epioxa as a high‑margin, differentiated asset within the company’s portfolio.

Looking ahead, Glaukos balances aggressive growth targets with disciplined capital allocation. Mid‑teens expense growth is earmarked for expanding the iDose TR network, launching Epioxa support programs, and advancing a deep pipeline that includes iStent Infinite, iDose TReX, and next‑generation corneal and retinal therapies. Competitive pressures in international glaucoma markets and potential payer delays for Epioxa constitute near‑term risks, yet the reaffirmed 2026 guidance and pipeline momentum suggest a multi‑year growth trajectory that could drive operating leverage and cash‑flow breakeven. Investors will watch how the company translates clinical innovation into sustainable market share across both glaucoma and rare‑disease segments.